Sylentis participates in several research projects that are being conducted in collaboration with other companies and institutions:
NanoPilot will set-up a flexible and adaptable pilot plant operating under GMP for the production of small batches of polymer-based nanopharmaceuticals, which exhibit significant potential in the field of drug-delivery particularly for the design of second-generation nanopharmaceuticals.
NanoPilot has received funding from the European Union Framework Programme for Research and Innovation Horizon 2020. This four-year long project’s objective is to set-up a pilot plant operating under Good Manufacturing Practice (GMP) for the production of polymer-based nanopharmaceuticals. The pilot plant will accelerate the development of nanomedicine, currently in its infancy within the pharmaceutical sector. Three different processes will be established for the production of three different nanopharmaceuticals.
The NABBA project is aimed to provide cutting edge and high medical and societal impact science for the multidisciplinary and intersectoral training of 13 ESRs. The ESRs will strongly benefit from a network of internationally recognized scientists in the field of nanobiotechnology, and the participation of companies with relevant interests in nanomedicine. The planned cooperation programmes between outstanding academic laboratories and Industries, will allow the circulation of ESRs and the opportunity for them to get acquainted with all the most sophisticated technological apparatus and with the most advanced Industrial manufacturing platforms and innovative strategies. These activities will represent attractive working conditions for the candidates of the NABBA program.
This consortium is headed by Sylentis and also comprises the University of Santiago de Compostela, the Complutense University of Madrid and the Basque Country University. The project aims to develop formulations that allow a more effective administration of the experimental drug bamosiran. It also seeks to design new active molecules that, by using the same technology but different glaucoma related targets, allow us to develop drug combinations that enhance the activity of this molecule. REF: GLAUKUS: Development of Personalized Glaucoma Treatments. Focus on Children Population and the Elderly. Reference: RTC-2016-4823-1.
This consortium is headed by Sylentis and also comprises the University of Santiago de Compostela, the University of Oviedo and the University of Valladolid. SEKEYE is a project on drug development that aims to generate alternatives to the current commercial solutions for the treatment of dry eye syndrome and its related ocular pain. To that end, the project will explore new traits of the molecule SYL1001 and will develop new compounds that could be used as single agents as well as in drug combinations with the drug SYL1001. REF: SEKEYE: Innovative Solutions to Treat Dry Eye Linked to Ocular Pain. REF: RTC-2016-4884-1.
The aim of the Surfeye Project is to develop new treatments for ocular inflammation associated with various allergens, as well as personalized treatments for ocular surface regeneration based on haematalogical derivatives. Personalized diagnostic systems will also be developed in order to treat the disease with the most appropriate therapies in each case and to monitor accurately the results of these treatments. Due to difficulties in the drug penetration process on the ocular surface and its low tolerance to chemical compounds -including the drug itself -, new, innovative drug delivery systems will be developed both for experimental and commercial active pharmaceutical ingredients
The objective of the TERET Project is to develop and improve new ophthalmic therapies against retinal diseases. These three indications are chronic diseases and currently lack effective treatments or leave a great deal of room for improvement, such as the administration of monoclonal antibodies by means of intravitreal injections.
As the basis of the project, biotechnological solutions based on the application of gen silencing and interference RNA and humanized monoclonal antibodies will be used.
The biotech companies Sylentis and LeadArtis will participate in the project, in collaboration with the LEITAT Technological Center and the Biomedical Research Networking Centre. The project is financed by the Spanish Ministry of Economy through the RETOS program.
Indreye is an industrial research Project that aims to increase the participants’ competitive advantages in the ophthalmology area by attempting to change the classic approaches to the diagnostics and treatment of dry eye syndrome. In this way, personalized treatments will be established for this syndrome that causes pain, classified from mild-moderate to severe dry eye syndrome. Personalized diagnostic systems will be developed for each level of dry eye syndrome with the aim of dealing with the disease with the most appropriate treatment.
The participants in the projects are Sylentis and S.A.L.V.A.T. laboratories, the Foundation for Biomedical Research of Hospital San Carlos, the Institute of Microelectronics of Barcelona IMB-CNM and the University of Oviedo. The project has been financed by the Spanish Ministry of Economy through the RETOS program.